Biosimilar Market Size, Share, Analysis Report

1    INTRODUCTION      

    1.1    Key Take Aways    
    1.2    Report Description    
    1.3    Markets Covered    
    1.4    Stakeholders    
    1.5    Research Methodology    
        1.5.1    Market Size    
        1.5.2    Market Share    
        1.5.3    Key Data Points From Secondary Sources    
        1.5.4    Key Data Points From Primary Sources

2 Research Methodology 
    2.1 Secondary Data 
           2.1.1 Key Data From Secondary Sources
    2.2 Primary Data 
           2.2.1 Key Data From Primary Sources
    2.3 Biosimilars Market Size Estimation 
           2.3.1 Bottom-Up Approach
           2.3.2 Top-Down Approach
    2.4 Biosimilars Market Breakdown & Data Triangulation 
    2.5 Assumptions for the Study

3 Executive Summary 
    3.1 Introduction 
    3.2 Conclusion

4 Premium Insights 
    4.1 Biosimilars: Market Overview 
    4.2 Geographic Analysis: Biosimilars Market, By Product 
    4.3 Biosimilars Market Size, By Application, 2018 vs 2024

5 Market Overview 
    5.1 Introduction 
    5.2 Market Dynamics 
           5.2.1 Drivers
                    5.2.1.1 Rising Incidences of Diseases
                    5.2.1.2 Increasing Demand for Biosimilar Drugs Due to Their Cost-Effectiveness
                    5.2.1.3 Growing Pressure to Curtail Healthcare Expenditure
                    5.2.1.4 Rising Geriatric Population
                    5.2.1.5 Strategic Collaborations Resulting in Enhanced Productivity and Clinical Trial Activities for Biosimilars
                    5.2.1.6 Increasing Government Support and Initiatives to Develop and Promote Biosimilars
           5.2.2 Restraints
                    5.2.2.1 Complexities in Manufacturing and High Costs
                    5.2.2.2 Innovative Strategies By Biologic Drug Manufacturers
           5.2.3 Opportunities
                    5.2.3.1 Emerging Markets
                    5.2.3.2 New Indications and Patent Expiry of Biologic Products
           5.2.4 Challenge
                    5.2.4.1 Stringent Regulatory Requirements to Adversely Affect Investments in Biosimilars
    5.3 Key Pipeline Products 
    5.4 Regulatory Outlook 
           5.4.1 North America
                    5.4.1.1 U.S.
                    5.4.1.2 Canada
           5.4.2 Europe
           5.4.3 Asia
                    5.4.3.1 China
                    5.4.3.2 India
                    5.4.3.3 Japan
                    5.4.3.4 South Korea
           5.4.4 Rest of the World
                    5.4.4.1 Brazil
                    5.4.4.2 Mexico
                    5.4.4.3 Argentina
                    5.4.4.4 Saudi Arabia
    5.5 Biosimilars Services Industry Insights 
           5.5.1 Introduction
           5.5.2 Contract Manufacturing Organizations
           5.5.3 Contract Research Organizations
           5.5.4 Other Services (Nonclinical & Bioinformatics)

6 Biosimilars Market, By Type of Product 
    6.1 Introduction 
    6.2 Recombinant Non-Glycosylated Proteins 
           6.2.1 Insulin
           6.2.2 Recombinant Human Growth Hormone (RHGH)
           6.2.3 Granulocyte Colony-Stimulating Factor (Filgrastim)
           6.2.4 Interferons
    6.3 Recombinant Glycosylated Proteins 
           6.3.1 Erythropoietin (EPO)
           6.3.2 Monoclonal Antibodies (MABS)
           6.3.3 Follitropin
    6.4 Recombinant Peptides 
           6.4.1 Glucagon
           6.4.2 Calcitonin

7 Biosimilars Market, By Type of Manufacturing 
    7.1 Introduction 
    7.2 In-House Manufacturing 
    7.3 Contract Manufacturing Organizations

8 Biosimilars Market, By Application 
    8.1 Introduction 
    8.2 Oncology 
    8.3 Chronic and Autoimmune Diseases 
    8.4 Blood Disorders 
    8.5 Growth Hormone Deficiency 
    8.6 Infectious Diseases 
    8.7 Other Applications

9 Biosimilars Market, By Region 
    9.1 Introduction 
    9.2 North America Biosimilars Market 
           9.2.1 U.S.
           9.2.2 Canada
    9.3 Europe Biosimilars Market
           9.3.1 Germany
           9.3.2 France
           9.3.3 U.K.
           9.3.4 Italy
           9.3.5 Spain
           9.3.6 Rest of Europe
    9.4 Asia Biosimilars Market 
           9.4.1 China
           9.4.2 India
           9.4.3 Japan
           9.4.4 South Korea
           9.4.5 Rest of Asia (RoA)
    9.5 Rest of the World (RoW) Biosimilars Market

10 Competitive Landscape 
     10.1 Overview 
     10.2 Biosimilars Market Market Share Analysis 
     10.3 Competitive Situation and Trends 
             10.3.1 Regulatory Approvals
             10.3.2 Agreements, Collaborations, and Partnerships
             10.3.3 Product Launches
             10.3.4 Acquisitions
             10.3.5 Expansions
             10.3.6 Other Developments

11 Company Profiles 
     11.1 Introduction 
     11.2 Pfizer Inc. 
     11.3 Sandoz International GmbH (A Division of Novartis International AG) 
     11.4 Teva Pharmaceutical Industries Ltd. 
     11.5 F. Hoffmann-La Roche Ltd. 
     11.6 Amgen Inc. 
     11.7 Biocon Ltd. 
     11.8 Dr. Reddy's Laboratories 
     11.9 Celltrion Inc. 
     11.10 Mylan Inc. 
     11.11 Samsung Bioepis

The Biosimilar Market has been segmented as below: (Accordingly)

By Manufacturing Type Analysis:

• In-house Manufacturing
• Contract Manufacturing Organizations

By Application Analysis:

• Oncology
• Blood Disorders
• Chronic & Autoimmune Diseases
• Growth Hormone Deficiency
• Infectious Diseases
• Other Applications

By Product Analysis

• Recombinant Non-Glycosylated Proteins
  • Insulin
  • Recombinant Human Growth Hormones
  • Granulocyte Colony-stimulating Factor
  • Interferons

• Recombinant Glycosylated Proteins
  • Erythropoietin
  • Monoclonal Antibodies
  • Follitropin

• Recombinant Peptides
  • Glucagon
  • Calcitonin

By Regional Analysis

    North America
    Europe
    Asia-Pacific
    Rest of the World